- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Foster City Today
By the People, for the People
Gilead Sciences Acquires Tubulis for $3 Billion
The deal adds a promising antibody-drug conjugate to Gilead's oncology pipeline.
Apr. 7, 2026 at 4:06pm
Got story updates? Submit your updates here. ›
Gilead Sciences' acquisition of Tubulis and its promising antibody-drug conjugate for ovarian cancer treatment signals the company's continued focus on expanding its oncology pipeline.Foster City TodayGilead Sciences, the Foster City, California-based pharmaceutical company, has announced the acquisition of Tubulis, a clinical-stage biotech firm, for $3.15 billion in upfront cash. The deal adds TUB-040, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer, to Gilead's oncology portfolio. Tubulis currently has two programs in clinical trials for solid tumor indications, and the acquisition includes additional contingent milestone payments of up to $1.85 billion.
Why it matters
The Tubulis acquisition is the latest in a series of strategic moves by Gilead to expand its oncology and autoimmune pipelines. The addition of TUB-040 strengthens Gilead's oncology offerings and aligns with the company's broader strategy to enhance its position in the rapidly evolving cancer treatment landscape.
The details
Gilead agreed to pay Tubulis $3.15 billion in upfront cash, with additional contingent milestone payments of up to $1.85 billion. The company is also eligible to receive up to approximately $58 million in additional contingent consideration related to its equity participation in Tubulis. The acquisition adds TUB-040, a promising ADC for the treatment of ovarian cancer, to Gilead's existing oncology portfolio. Tubulis currently has two programs in clinical trials for solid tumor indications.
- Gilead announced the acquisition on April 7, 2026.
- Tubulis raised 60 million euros in a Series B financing round in May 2022, and an additional 128 million euros in a Series B2 round in March 2024.
The players
Gilead Sciences
A biopharmaceutical company based in Foster City, California, focused on developing and commercializing innovative medicines for the treatment of life-threatening diseases, including cancer and autoimmune disorders.
Tubulis
A clinical-stage biotech company that develops antibody-drug conjugates (ADCs) for the treatment of solid tumor indications.
What’s next
Gilead will work to integrate Tubulis' operations and pipeline into its own oncology and autoimmune research and development efforts, with the goal of advancing TUB-040 and Tubulis' other clinical programs.
The takeaway
Gilead's acquisition of Tubulis is the latest in a series of strategic moves by the company to expand its oncology and autoimmune pipelines. The addition of TUB-040, a promising ADC for ovarian cancer, strengthens Gilead's position in the rapidly evolving cancer treatment landscape and aligns with the company's broader growth strategy.
